Genmab: Janssen applies for approval for lung cancer drug in the US

Genmab's collaborative partner Janssen has submitted a Biologics License Application to the FDA for the lung cancer treatment amivantamab, which was developed from the basis on Genmab's Duobody technology.
Photo: PR / Genmab
Photo: PR / Genmab
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

The license approval application to the US Food and Drug Administration concerns patients with metastatic non-small cell lung cancer (NSCLC) with a particular set of mutations. Furthermore, patients need to have had relapses after being treated with chemotherapy, according to an announcement from Genmab.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading